November 2019 By Tom Newsom-Davis, BTOG Vice-Chair 1st Line Osimertinib Overall Survival Results: FLAURA The overall survival (OS) date from the FLAURA study was presented at the Presidential Session of ESMO 2019, following publication of the Progression Free Survival (PFS) … Read More
October 2019 By Tom Newsom-Davis, BTOG Vice-Chair Treatment of RET-Fusion NSCLC: LIBRETTO-001 RET fusions are found in a number of different cancer and account for approximately 2% of NSCLC. Although rare, they are predominantly found in younger patients, non-smokers or … Read More
Registration is now open for the International Mesothelioma Interest Group meeting, iMig 2020, in Brisbane, Australia, 25th-28th March, 2020. The closing date for abstracts is 30th October and can be submitted online. The event will bring together over 500 delegates from … Read More
The results of EORTC’s survey into the impact of the CONVERT trial have been published in Lung Cancer journal. This will be of particular interest to the BTOG members who took part in the survey.
The Systemic Anti-Cancer Therapy (SACT) team at Public Health England has released the final version of the workbook with the following documents: Companion brief detailing the official trust comments on their data Evaluation report describing the feedback received from trusts … Read More
March 2019 By Liz Darlison, Head of Services and Clinical Nurse Specialist for Mesothelioma UK and Professor James Spicer, BTOG Steering Committee Member. An Essential Update on mesothelioma, organised by the British Thoracic Oncology Group and Mesothelioma UK, was held … Read More
We are pleased to announce that Tom Newsom-Davis has been appointed Vice Chair of the BTOG Steering Committee. Tom is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He has been … Read More
February 2019 Four first time attendees at BTOG 2019 kindly took the time to write a blog about their experience and thoughts on the conference.
December 2018 By Sanjay Agrawal, Consultant Respiratory Intensivist As specialists with an interest in thoracic oncology, we want our patients to have the best outcome whether that’s as a result of screening, early diagnosis, surgery, radiotherapy, chemotherapy or … Read More
The Second Edition of the IASLC Staging Manual in Thoracic Oncology reports on the latest revisions of the tumor, node and metastasis (TNM) classifications of thoracic malignancies, namely, lung cancer, malignant pleural mesothelioma, carcinoma of the esophagus and of the … Read More